Results 91 to 100 of about 32,890 (266)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Risk factors for early postoperative complications after minimally invasive surgery in pediatric ulcerative colitis

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective To report a single‐center experience with a multidisciplinary minimally invasive surgical approach for pediatric ulcerative colitis (UC) and identify risk factors for early postoperative complications (EPC). Methods A retrospective analysis was conducted on UC patients followed at the Gastroenterology Unit of Meyer Children's ...
Martina Di Benedetto, Luca Scarallo, Sara Renzo, Sara Naldini, Monica Paci, Jacopo Barp, Federico Perna, Emilio Paolo Emma, Riccardo Coletta, Stefano Scaringi, Paolo Lionetti   +10 more
wiley   +1 more source

Use of biological drugs in patients with psoriasis and psoriatic arthritis in italy: Results from the PSONG survey [PDF]

, 2018
This Italian multicenter retrospective study compared the drug survival and efficacy of differentanti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients.
Berardesca, E, Bernardini, N, Bianchi, L, Chimenti, S, Costanzo, A., D'Epiro, S, De Simone, C, Narcisi, A, Orsini, D, Peris, K, Potenza, Mc, Richetta, A, Teoli, M, Zangrilli, A   +13 more
core  

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas, Agca, Ait-Oufella, Albert, Alexander, Alexander, Alexander, Alexander, Andersen, Aziz, Babelova, Bellosta, Bevilacqua, Bhaskar, Blom, Boekholdt, Boekholdt, Bostrom, Brånén, Bulgarelli, Bulgarelli, Burke, Cai, Cannon, Casas, Collins, Cronstein, Dahlman-Ghozlan, Danesh, Davenport, Davey Smith, Davidson, DeOliveira, Devlin, Dinarello, Duewell, Duivenvoorden, Eisenhardt, Elango, Elhage, Ettehad, Flood, Fraser, Freigang, Fulgoni, Galkina, Galkina, Garlanda, Grassia, Grassia, Greenberg, Hansson, Hauer, Herder, Holmes, Hu, Huang, Huber, Interleukin 1 Genetics Consortium, Ivandic, Kalliolias, Kaptoge, Kimura, Kinlay, Kirii, Kleinman, Koltsova, Kureishi, Kwak, Lee, Leite, Leite, Lewington, Liao, Libby, Libby, Macritchie, Maddaluno, Maeda, Maffia, Makheja, Margaritis, McInnes, Menu, Micha, Mihaylova, Mira, Mohler, Montezano, Mulhaupt, Murad, Myasoedova, Myung, Nakata, Nicholls, O'Donoghue, Ogdie, Ohta, Pauling, Peters, Qiao, Quarck, Rajamäki, Rastogi, Reiss, Rezaie-Majd, Ridker, Ridker, Rincón, Robertson, Romano, Rosenson, Rosenson, Roubille, Ryan, Rössig, Saeed, Sage, Sarwar, Sattar, Scalia, Schett, Schieffer, Schuett, Serruys, Sever, Sever, Shah, Shaposhnik, Singh, Sirtori, Sniderman, Soedamah-Muthu, Solomon, Southan, Souverein, Sprague, Srikakulapu, Strober, Sukovich, Swerdlow, Swirski, Talmud, Tay, Teng, Thompson, Tits, Toedter, Turunen, Tzellos, Walker, Wang, Wang, Watson, Weintraub, Welsh, Welsh, Welsh, Welsh, Weng, Wensley, White, Wilensky, Willeit, Willis, Wong, Woodward, Xanthoulea, Ye, Ye, Yilmaz, Youssef, Zalewski, Zhao   +173 more
core   +2 more sources

Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies

Journal of Clinical Medicine
Background: Anti-tumour necrosis factor (TNF) agents are effective in Crohn’s disease (CD), but some patients lose responsiveness and require alternative biologic therapy.
M. Sharip, Nilanga Nishad, L. Pillay, Nilkantsingh Goordoyel, Samuel Goerge, S. Subramanian   +5 more
semanticscholar   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

Sexual Dysfunctions in Psoriatic Patients [PDF]

, 2015
Psoriasis is a chronic, immune-mediated disorder with a worldwide occurrence characterized by well-defined infiltrated erythematous papules and plaques, covered by silvery white or yellowish scales.
Georgescu, Simona Roxana, Sarbu, Alexandra Elenda, Sarbu, Maria Isabela, Tampa, Mircea   +3 more
core   +2 more sources

SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype [PDF]

, 2018
Objective: To explore the effects of SERPINB3 administration in murine lupus models with a focus on lupus-like nephritis. Methods: 40 NZB/W F1 mice were subdivided into 4 groups and intraperitoneally injected with recombinant SERPINB3 (7.5 \u3bcg/0.1 mL ...
Beggio, M, Biasiolo, A, Cappon, A, Cavicchioli, L, Codolo, G, Doria, A., Gatto, M, Ghirardello, A, Luisetto, R, Maggioni, G, Pontisso, P, Saccon, F, Venturini, R   +12 more
core   +2 more sources

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks.

British Journal of Dermatology
BACKGROUND ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity, and potency as well as clinical pharmacokinetics and ...
A. Blauvelt, K. Papp, M. Trivedi, C. Barragan, V. Chow, D. Mytych, P. Yamauchi, Jeffrey Crowley, J. Franklin   +8 more
semanticscholar   +1 more source